Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Ebronucimab Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-59267
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Lyophilized
浓度
1 mg/mL
纯化类型
Protein A
保存液
25mM histidine, pH 6.2, with 8% sucrose, 0.01% Tween 80
内含物
no preservative
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Dry ice (international)
RRID
产品详细信息
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
靶标信息
Ebronucimab, also known as AK102, is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of cholesterol homeostasis. The PCSK9 gene, located on chromosome 1p32.3, encodes the proprotein convertase subtilisin/kexin type 9 (PCSK9), which is a 692-amino acid protein pivotal in cholesterol metabolism. Structurally, PCSK9 comprises a signal peptide, a pro-domain, a catalytic domain, and a cysteine-histidine rich C-terminal domain. The signal peptide is cleaved in the endoplasmic reticulum, allowing the mature protein to be secreted. Functionally, PCSK9 binds to low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, leading to their degradation and hence increased levels of circulating LDL cholesterol. Variants of PCSK9 can significantly influence an individual's cholesterol levels and cardiovascular risk. Therapies targeting PCSK9, such as monoclonal antibodies, are effective in lowering LDL cholesterol, providing significant cardiovascular benefits.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
